Prostate-Specific Antigen Kinetics in Clinical Decision-Making During Active Surveillance for Early Prostate Cancer-A Review

European Urology

Volumn 54, Issue 3, 2008, Pages 505-516

  van den Bergh, Roderick C N ^a   Roemeling, Stijn ^a   Roobol, Monique J ^a   Wolters, Tineke ^a   Schröder, Fritz H ^a   Bangma, Chris H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Active surveillance; Prognosis; Prostate cancer; PSA doubling time; PSA velocity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CALCULATION; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONSENSUS; ENZYME KINETICS; FOLLOW UP; HEALTH SURVEY; MATHEMATICS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

DECISION MAKING; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 47949125730     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.040     Document Type: Review

References (37)

1. Bratt O. Watching the face of Janus-active surveillance as a strategy to reduce overtreatment for localised prostate cancer. Eur Urol 50 (2006) 410-412
2. Warlick C., Trock B.J., Landis P., Epstein J.I., and Carter H.B. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98 (2006) 355-357
3. Carter H.B., Ferrucci L., Kettermann A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521-1527
4. Schroder F.H., Roobol M.J., van der Kwast T.H., Kranse R., and Bangma C.H. Does PSA velocity predict prostate cancer in pre-screened populations?. Eur Urol 49 (2006) 460-465
5. McLaren D.B., McKenzie M., Duncan G., and Pickles T. Watchful waiting or watchful progression?: prostate-specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 82 (1998) 342-348
6. Zietman A.L., Thakral H., Wilson L., and Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol 166 (2001) 1702-1706
7. Carter C.A., Donahue T., Sun L., et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21 (2003) 4001-4008
8. Connolly D., Black A., Murray L.J., Napolitano G., Gavin A., and Keane P.F. Methods of calculating prostate-specific antigen velocity. Eur Urol 52 (2007) 1044-1051
9. Vollmer R.T., Egawa S., Kuwao S., and Baba S. The dynamics of prostate-specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer 94 (2002) 1692-1698
10. Carter H.B., Kettermann A., Ferrucci L., Landis P., and Metter E.J. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 70 (2007) 685-690
11. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125-135
12. King C.R., Freedland S.J., Terris M.K., et al. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology 69 (2007) 732-737
13. D'Amico A.V., Renshaw A.A., Sussman B., and Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. Jama 294 (2005) 440-447
14. Eggener S.E., Roehl K.A., Yossepowitch O., and Catalona W.J. Prediagnosis prostate-specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol 176 (2006) 1399-1403
15. Goluboff E.T., Heitjan D.F., DeVries G.M., Katz A.E., Benson M.C., and Olsson C.A. Pretreatment prostate-specific antigen doubling times: use in patients before radical prostatectomy. J Urol 158 (1997) 1876-1878 discussion 1878-9
16. Hanks G.E., Hanlon A.L., Lee W.R., Slivjak A., and Schultheiss T.E. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34 (1996) 549-553
17. Egawa S., Arai Y., Tobisu K., et al. Use of pretreatment prostate specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3 (2000) S11
18. Freedland S.J., Dorey F., and Aronson W.J. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 57 (2001) 476-480
19. Guidelines on prostate cancer. 2007. European Association of Urology Web site. http://www.uroweb.org. Accessed February 11, 2008.
20. Clinical practice guidelines in oncology. Prostate cancer v.2.2007. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed February 11, 2008.
21. Choo R., Klotz L., Deboer G., Danjoux C., and Morton G.C. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int 94 (2004) 295-298
22. Roemeling S., Roobol M.J., de Vries S.H., et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome. Eur Urol 51 (2007) 1244-1251
23. Carter H.B., Walsh P.C., Landis P., and Epstein J.I. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167 (2002) 1231-1234
24. Schmid H.P., McNeal J.E., and Stamey T.A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71 (1993) 2031-2040
25. Khan M.A., Carter H.B., Epstein J.I., et al. Can prostate-specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?. J Urol 170 (2003) 2274-2278
26. Khatami A., Aus G., Damber J.E., Lilja H., Lodding P., and Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 120 (2007) 170-174
27. Stephenson A.J., Aprikian A.G., Souhami L., et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 59 (2002) 652-656
28. Patel M.I., DeConcini D.T., Lopez-Corona E., Ohori M., Wheeler T., and Scardino P.T. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171 (2004) 1520-1524
29. Fall K., Garmo H., Andren O., et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99 (2007) 526-532
30. Choo R., Klotz L., Danjoux C., et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167 (2002) 1664-1669
31. Van den Bergh R.C., Roemeling S., Roobol M.J., Roobol W., Schröder F.H., and Bangma C.H. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52 (2007) 1560-1563
32. Soletormos G., Semjonow A., Sibley P.E., et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 51 (2005) 1342-1351
33. Ross P.L., Mahmud S., Stephenson A.J., Souhami L., Tanguay S., and Aprikian A.G. Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations. Urology 64 (2004) 323-328
34. Venkitaraman R., Norman A.R., Iqbal J., et al. Clinical implications of introducing a new PSA assay. Int Urol Nephrol (2008)
35. Carter H.B., Morrell C.H., Pearson J.D., et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 52 (1992) 3323-3328
36. D'Amico A.V., and Barry M.J. Prostate cancer prevention and finasteride. J Urol 176 (2006) 2010-2012 discussion 2012-3
37. Fleshner N., Gomella L.G., Cookson M.S., et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 28 (2007) 763-769